Shares of Bio-Techne Corp. slipped 4.01% to $48.81 Monday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index rising 1.01% to 6,699.38 and the Dow ...

Bio-Techne develops specialized reagents and diagnostic solutions for global research and clinical markets in the life ...

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Bio-Techne (TECH) is back in focus after institutional ...

Life sciences company Bio-Techne (NASDAQ:TECH) reported Q4 CY2025 results , but sales were flat year on year at $295.9 million. Its non-GAAP profit of $0.46 per share was 5.8% above analysts’ ...

MINNEAPOLIS, Oct. 31, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) announced that its Board of Directors has decided to pay a dividend of $0.08 per share for the quarter ended September ...

Dr. Matt McManus to transition from his role as President, Diagnostics and Spatial Biology Segment, effective March 1, 2026 Steve Crouse, Senior Vice President of Bio-Techne's Analytical Solutions ...

A live webcast of the presentations can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir ...

Techne Corporation (Nasdaq: TECH), a global provider of life science tools, reagents and diagnostic products, visits the ...

Bio-Techne (TECH) prevailed on another claim that Miltenyi Biotec KG commercialized antibodies developed based on information obtained by reverse engineering Bio-Techne’s proprietary R&D Systems ...

TD Cowen 46th Annual Health Care Conference March 3, 2026 11:10 AM ESTCompany ParticipantsKim Kelderman - CEO, President ...

Shares of Bio-Techne Corp. TECH rallied 1.82% to $54.87 Monday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 0.83% to 6,795.99 and ...